Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3565 | Self-questionnary Wiki | 1.00 |
| drug3055 | Practice details Wiki | 0.71 |
| drug615 | Blood test Wiki | 0.71 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
Since the start of this epidemic, numerous clinical and fundamental studies have been conducted to best adapt the individual management of COVID-19 cases [1-6]. In parallel with this work, it is necessary to better understand the characteristics of the epidemic in the general population but also in the population working in healthcare settings more exposed to SARS-CoV-2. Seroprevalence studies are therefore particularly useful in order to understand the collective immunization rate and the factors that can explain this immunization.
Description: Rate of presence
Measure: rate of presence of anti-SARS-CoV-2 antibodies (Ig G _ Ig M) among employees working in a GHT Haute Bretagne health establishment. Time: at inclusion visitDescription: Sensitivity
Measure: a) Validation of the Biotech NG test: Time: at inclusion visitDescription: Specificity
Measure: a) Validation of the Biotech NG test: Time: at inclusion visitDescription: agreement between observers (kappa coefficient)
Measure: a) Validation of the Biotech NG test: Agreement between observers (kappa coefficient) for IgG Time: at inclusion visitDescription: agreement between observers (kappa coefficient)
Measure: a) Validation of the Biotech NG test: Agreement between observers (kappa coefficient) for IgM. Time: at inclusion visitDescription: Demographic characteristics (age, sex)
Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function: Time: At inclusion visitDescription: - Professional characteristics (establishment, profession, service).
Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function: Time: At inclusion visitDescription: - Management of confirmed or probable COVID-19 patients
Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function: Time: At inclusion visitDescription: - From contact with confirmed or probable COVID-19 professionals.
Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function: Time: At inclusion visitDescription: - From contact in his personal circle with COVID-19 confirmed or probable persons.
Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function: Time: At inclusion visitDescription: - Episodes of symptoms suggestive of COVID-19
Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function: Time: At inclusion visitDescription: - The existence of a chronic immunomodulatory pathology
Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function: Time: At inclusion visitDescription: - The existence of smoking
Measure: b) Risk of presence of anti SARS-CoV-2 antibodies in function: Time: At inclusion visitDescription: - The use of materials adapted to good hygiene practices
Measure: c) Risk of presence of anti SARS-CoV-2 antibodies in function: Time: At inclusion visitDescription: - Service organization
Measure: c) Risk of presence of anti SARS-CoV-2 antibodies in function: Time: At inclusion visitDescription: depending on the work sector (COVID dedicated or not) and depending on the profession: - Rate of employees who changed their tobacco consumption
Measure: d) Description of the experience and behavioral changes related to the epidemic, Time: at Day 0Description: depending on the work sector (COVID dedicated or not) and depending on the profession: - Description of the reasons for modifying tobacco consumption
Measure: d) Description of the experience and behavioral changes related to the epidemic, Time: at Day 0Description: depending on the work sector (COVID dedicated or not) and depending on the profession: - Rate of employees who changed their alcohol consumption
Measure: d) Description of the experience and behavioral changes related to the epidemic, Time: at Day 0Description: depending on the work sector (COVID dedicated or not) and depending on the profession: - Description of the reasons for modification of alcohol consumption
Measure: d) Description of the experience and behavioral changes related to the epidemic, Time: at Day 0Description: depending on the work sector (COVID dedicated or not) and depending on the profession: - Rate of employees who have changed their eating habits
Measure: d) Description of the experience and behavioral changes related to the epidemic, Time: at Day 0Description: depending on the work sector (COVID dedicated or not) and depending on the profession: - Description of sleep changes
Measure: d) Description of the experience and behavioral changes related to the epidemic, Time: at Day 0Description: depending on the work sector (COVID dedicated or not) and depending on the profession: - Description of lived experience and perceived stress
Measure: d) Description of the experience and behavioral changes related to the epidemic, Time: at Day 0Description: For employees identified as COVID "certain or probable" * Percentage of employees with antibodies (IgG and IgM) against SARS CoV-2 on D30 and D90.
Measure: e) Evolution of seroprevalence over time: Time: At Day30Description: For employees identified as COVID "certain or probable" * Evolution of the kinetics of antibodies (IgG and IgM) against SARS CoV-2 on D30 and D90.
Measure: e) Evolution of seroprevalence over time: Time: At Day 90Description: For the random sample of employees with follow-up on D90: Percentage of employees with antibodies (IgG and IgM) against SARS CoV-2
Measure: e) Evolution of seroprevalence over time: Time: At Day 90Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports